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A B S T R A C T 
Objective: To investigate the effectiveness of a 
secondary stroke prevention protocol in the general 
out-patient clinic.
Design: Cohort study with pre- and post-
intervention comparisons.
Setting: Two general out-patient clinics in Hong 
Kong.
Patients: Ischaemic stroke patients who had long-
term follow-up in two clinics were recruited. The 
patients of one clinic received the intervention 
(intervention group) and the patients of the second 
clinic did not receive the intervention (control 
group). The recruitment period lasted for 6 months 
from 1 September 2008 to 28 February 2009. The 
pre-intervention phase data collection started within 
this 6-month period. The protocol implementation 
started at the intervention clinic on 1 April 2009. 
The post-intervention phase data collection started 
9 months after the protocol implementation, and ran 
for 6 months from 1 January 2010 to 30 June 2010.
Main outcome measures: Clinical data before and 
after the intervention, including blood pressure, 
glycated haemoglobin level, low-density lipoprotein 
level and prescription pattern, were compared 
between the two groups to see whether there was 
enhancement of secondary stroke management.
Results: A total of 328 patients were recruited into 
the intervention group and 249 into the control 
group; data of 256 and 210 patients from these groups 
were analysed, respectively. After intervention, there 
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Introduction
Stroke is the second commonest cause of death 
worldwide1 and the fourth leading cause of death 
in Hong Kong.2 Stroke is also the commonest cause 
of permanent disability in adults. Patients with 
stroke are at high risk for recurrent stroke and other 
major vascular events. As the ageing population is 
New knowledge added by this study
• A standard secondary stroke prevention protocol can significantly improve the control of cardiovascular risk 
factors in ischaemic stroke patients. 
• Implementation of such a programme is effective and feasible in local primary care.
Implications for clinical practice or policy
• This study supports more widespread use of a secondary stroke prevention programme in the setting of a 
general out-patient clinic.
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increasing in most developed countries, stroke will 
remain a major burden to patients’ families and carers, 
the health care system, and the community. According 
to local data from Hong Kong, cerebrovascular disease 
was the principal diagnosis for about 26 500 in-patient 
discharges and deaths in all hospitals and accounted 
for 7.5% of all deaths in 2012.3 The mortality rate was 
ORIGINAL ARTICLE
were significant reductions in mean (± standard 
deviation) systolic blood pressure (135.2 ± 17.5 mm 
Hg to 127.7 ± 12.2 mm Hg), glycated haemoglobin 
level (7.2 ± 1.0% to 6.5 ± 0.8%), and low-density 
lipoprotein level (3.4 ± 0.8 mmol/L to 2.8 ± 1.3 
mmol/L) in the intervention group (all P<0.01). 
There were no significant reductions in mean systolic 
blood pressure, glycated haemoglobin level, or low-
density lipoprotein level in the control group. There 
was a significant increase in statin use (P<0.01) in 
both clinics.
Conclusion: Through implementation of a clinic 
protocol, the standard of care of secondary stroke 
prevention for ischaemic stroke patients could be 
improved in a general out-patient clinic. 
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基層醫療層面上針對缺血性中風患者而實施的二
級預防中風計劃
蔡宇均、韓璟浩、李梓強、龔敬樂、林璨
目的：探討普通科門診服務中二級預防中風計劃的有效性。
設計：干預前後的隊列研究比較。
安排：香港兩間普通科門診診所。
患者：本研究包括曾於兩間診所接受長期隨訪的缺血性中風患者。其
中一間診所的中風患者接受干預（干預組），另一間診所的患者並無
接受干預（對照組）。參與者的招聘期由2008年9月1日至2009年2月
28日。在這6個月期間向他們收集資料，作為干預前的數據。2009年
4月1日開始實施二級預防中風計劃。計劃實施9個月後（即從2010年1
月至2010年6月）開始收集患者資料作為干預後的數據，為期6個月。
主要結果測量：干預前後的臨床資料，包括血壓、糖化血紅蛋白、低
密度脂蛋白和處方模式。然後比較兩組數據來探討二級預防中風計劃
是否有效。
結果：研究把328名患者納入干預組，249名患者納入對照組，並就兩
組患者的數據資料（干預組256名、對照組210名）進行分析。二級預
防中風計劃實施後，干預組在以下三方面的平均（± 標準差）水平顯
著下降：收縮壓（135.2 ± 17.5 mm Hg減至127.7 ± 12.2 mm Hg）、
糖化血紅蛋白（7.2 ± 1.0%減至6.5 ± 0.8%）和低密度脂蛋白（3.4 ± 
0.8 mmol/L減至2.8 ± 1.3 mmol/L）[P<0.01]。對照組在這三方面
並無顯著減少。兩間診所的患者在使用他汀類藥物方面明顯上升
（P<0.01）。
結論：二級預防中風計劃實施後，普通科門診服務中缺血性中風患者
的護理得到改善。
significantly higher in patients with stroke recurrence 
than in those without.4,5 Prevention of recurrent 
stroke offers great potential for reducing the burden 
of this disease.
 Over 80% of all strokes are ischaemic stroke. 
There are effective strategies for secondary 
prevention of ischaemic stroke, which are 
summarised as follows6:
(1) Modification of lifestyle risk factors (smoking, 
alcohol consumption, obesity, physical 
inactivity).
(2) Modification of vascular risk factors 
(hypertension, hypercholesterolaemia, diabetes).
(3) Antiplatelet therapy for non-cardioembolic 
ischaemic stroke.
(4) Anticoagulation for cardioembolic stroke.
(5) Intervention for symptomatic carotid stenosis.
 As stroke patients need lifelong monitoring 
and control of risk factors, family physicians play the 
most important role in providing secondary stroke 
prevention care. However, despite the availability 
of evidence-based guidelines, studies show that 
adherence to these preventive strategies by physicians 
is poor.7-11 Local Hong Kong data about secondary 
stroke prevention in primary care are largely lacking. 
This study aimed to review the clinical effectiveness 
of a secondary stroke prevention programme in a 
general out-patient clinic (GOPC).
Methods
This was a cohort study of pre- and post-intervention 
comparison between patients receiving or not 
receiving the intervention to ascertain the effect of a 
secondary stroke prevention programme on clinical 
outcomes. 
Clinic setting
The Lek Yuen GOPC was selected as the intervention 
site where the secondary stroke prevention 
programme was implemented. Another clinic, the 
Ma On Shan GOPC, was selected as the control site, 
where usual care was provided. Both clinics are large 
public primary care clinics under the management 
of the Department of Family Medicine of the New 
Territories East Cluster of the Hospital Authority. 
Both clinics are accredited Family Medicine 
Training Centres with similar service throughput 
annually, covering a population of around 600 000 
and providing approximately 30 000 attendances 
monthly.
 Most of the stroke patients in the clinics are 
referred from the public hospitals. The patients 
usually have a history of minor stroke with good 
functional recovery and are clinically stable. 
Clinic protocol development and 
implementation
A protocol of secondary stroke prevention (Box) 
was developed with reference to evidence-based 
guidelines (mainly according to the American Heart 
Association and American Stroke Association stroke 
guidelines).12-14
1. Record smoking and alcohol status, with appropriate management
2. Record amount of exercise (>30-minute moderate activity), give advice
3. Record BMI: aim for BMI <23 kg/m2, with management for obesity
4. Check blood pressure at each visit
 - aim for <140/90 mm Hg for patients without diabetes
 - aim for <130/80 mm Hg for patients with diabetes
 - be aware of symptomatic hypotension
 - less tight control in the presence of carotid stenosis 
5. Annual blood test for fasting blood glucose and lipids
6. Patients with diabetes: aim for normoglycaemia, HbA1c <7%
7. Cholesterol: aim for LDL <1.9 mmol/L
 - recheck lipids and liver function test after initiation of a statin 
8. Antithrombotic for patients with ischaemic stroke unless contra-indicated, 
options:
 - aspirin
 - aspirin + extended-release dipyridamole
 - clopidogrel
9. Warfarin for patients with atrial fibrillation unless contra-indicated
BOX.  Clinic protocol and treatment goals of secondary stroke prevention for 
ischaemic stroke patients
Abbreviations: BMI = body mass index; HbA
1c
 = glycated haemoglobin; LDL = low-
density lipoprotein
  #  Choi et al #
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Study design 
The target population of the study was all the 
ischaemic stroke patients with long-term follow-up 
in the two clinics. The recruitment period lasted for 6 
months from 1 September 2008 to 28 February 2009. 
As the usual follow-up interval of long-term patients 
is about 3 to 4 months, the 6-month recruitment 
period included all stroke patients who have 
regular follow-up. The pre-intervention phase data 
collection started within this 6-month period. The 
protocol implementation started at the intervention 
clinic on 1 April 2009. The post-intervention phase 
data collection started 9 months after the protocol 
implementation, that is, for 6 months from 1 January 
2010 to 30 June 2010. 
Sampling
The clinical data were collected by reviewing the 
medical records of all patients assigned with the 
International Classification of Primary Care coding 
of K90 (stroke/cerebrovascular accident) or K91 
(cerebrovascular disease). Only those patients 
diagnosed with ischaemic stroke and who had at 
least two consecutive follow-up visits within the 
recruitment period were included. Patients who had 
a history of haemorrhagic stroke were excluded. In 
order to exclude patients with sporadic follow-up, 
only those patients with two consecutive follow-up 
visits in the post-intervention phase were regarded 
as eligible for data collection. Those patients 
without two consecutive follow-up visits in the post-
intervention phase were classified as dropouts. 
Protocol implementation
One month before initiation of the protocol, two 
1-hour training sessions were arranged for medical 
officers and nurses in the intervention clinic. 
During the training sessions, the treatment goals 
for secondary ischaemic stroke prevention and 
the relevant clinical evidence were presented. The 
workflow and applicability of the protocol were 
also discussed. Medical officers were required to 
have good documentation of all the lifestyle and 
cardiovascular risk factors of the ischaemic stroke 
patients and provide care according to the protocol. 
Nurses were trained to be familiar with the treatment 
goals and provide patient education and lifestyle 
modification interventions in line with the doctors’ 
referrals. Allied health services such as a dietitian, 
smoking cessation clinic, diabetes complication 
screening programme, and patient empowerment 
programmes for diabetic and hypertensive patients 
were available in both the intervention and control 
clinics. Doctors in the intervention clinic were 
encouraged to refer appropriate patients to these 
services. There was no additional consultation time 
allocated to these patients. In order to monitor 
progress, the electronic consultation notes were 
reviewed monthly for each patient to assess 
compliance with the protocol. If suboptimal care 
was noted, an electronic reminder with appropriate 
management advice was issued to the patient’s 
electronic medical record. The consulting doctor 
would then be able to provide the appropriate 
management at the next follow-up. Throughout 
the protocol implementation period, interim clinic 
meetings were held quarterly to present the data for 
protocol compliance with the medical and nursing 
staff of the intervention clinic. 
 In the control clinic, no specific protocol was 
applied. Medication prescription and adjustment 
was based solely on the physicians’ discretion. 
The drug formulary was the same in both clinics. 
Statins were introduced to both clinic formularies 
in July 2009. There were no training sessions for 
doctors and nursing staff in the control clinic, and 
no electronic reminders or interim meetings for 
progress monitoring.
Data collection
Baseline characteristics on sex, age, chronic illness 
status, chronic drug use, laboratory results, and 
blood pressure (BP) values were extracted from 
the Clinical Data Analysis and Reporting System. 
The latest laboratory results and BP values within 
the data collection period were taken as the study 
data. Individual case records were also reviewed for 
the following lifestyle parameters: smoking status, 
alcohol consumption, body mass index (BMI), and 
exercise and diet history.
Statistical analysis
All statistical analysis was performed using 
the Statistical Package for the Social Sciences 
(Windows version 20.0; SPSS Inc, Chicago [IL], 
US). Continuous variables were expressed as mean 
and standard deviation. Baseline comparisons were 
made with the Student’s t test or the Chi squared test 
as appropriate. The mean BP, glycated haemoglobin 
(HbA1c) level, and low-density lipoprotein (LDL) 
level before and after intervention were compared 
by paired-samples t test in both the intervention and 
control clinics. 
Results
In the intervention clinic, 328 patients were 
recruited to the intervention group and 72 dropped 
out. In the control clinic, 249 were recruited to the 
control group and 39 dropped out. The reasons for 
dropping out are shown in Table 1. More patients 
in the intervention group than in the control group 
dropped out due to restroke (9 vs 2, respectively) 
and death (22 vs 11, respectively), but these were not 
statistically significant due to the small number of 
#  Secondary stroke prevention protocol  # 
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patients. In both the intervention and control groups, 
most of the patients who died had no medication 
changes during the intervention period (Table 1). 
 A total of 256 patients in the intervention 
group and 210 in the control group were recruited for 
data analysis. At baseline, there were no significant 
differences in the demographic and cardiovascular 
risk factor profiles between the two groups, except 
that patients in the intervention group had a higher 
mean LDL level and a lower mean diastolic BP 
(Table 2).
 After the intervention period, significant 
improvements in systolic BP, HbA1c and LDL levels 
were observed in the intervention group (Table 3). 
There were significant improvements in all lifestyle 
modification parameters (alcohol and smoking 
status, obtaining exercise and diet history, and BMI 
measurement) in the intervention group (P<0.01), 
and the control group had improvements in smoking 
status (P<0.01) and BMI measurement (P<0.05) 
[Table 3]. 
 There was no significant increase in the number 
of antihypertensive drugs prescribed in either group 
(Table 4). Approximately 96% of patients were taking 
an antiplatelet after the intervention period in both 
clinics (Table 4) and the antiplatelet was always 
aspirin. The proportion of patients prescribed statins 
increased significantly in both groups since the 
introduction of simvastatin to the GOPC formulary 
in 2009. However, the overall proportion of statin 
use was still below 50%. Statins were less frequently 
prescribed to patients older than 80 years (Table 5). 
 Statins were stopped for 1.6% of patients in the 
intervention group and 4.3% in the control group 
(Table 4). Statins were discontinued because of 
dyspepsia for all patients in the intervention group. 
The reasons for stopping statins for the control 
group were dyspepsia, myalgia, mild liver function 
derangement, hypotension, hypoglycaemia, and 
drug-induced hepatitis. Only two patients in the 
control group required emergency admission for 
hypoglycaemia during the intervention period. 
There was no restroke in the intervention group 
TABLE 1.  Reasons for dropping out of the study
No. (%) P value
Intervention group Control group
No. of patients in initial recruitment period 328 249 -
No. of patients dropping out 72 (22.0) 39 (15.7) 0.06
Reasons for dropping out
Death 22* (6.7) 11† (4.4) 0.24
Death due to stroke 2‡ (0.6) 1§ (0.4) 0.73
Follow-up in other GOPCs 21 (6.4) 13 (5.2) 0.55
Follow-up in medical clinics 20 (6.1) 13 (5.2) 0.65
Due to restroke 9|| (2.7) 2¶ (0.8) 0.09
Due to adverse drug effects 0 0 -
Defaulted follow-up 9 (2.7) 2 (0.8) 0.09
Abbreviation: GOPC = general out-patient clinic
* Two patients had changes in medication during the intervention period
† One patient had changes in medication during the intervention period
‡ Death due to stroke 1 month (one follow-up visit) and 4 months (two follow-up visits) after the intervention period 
§ Death due to stroke 5 months (one follow-up visit) after the intervention period 
|| Only two had restroke after the intervention period with no change in medication
¶ All had restroke before the intervention period
TABLE 2.  Baseline demographic data
Demographics Intervention group 
(n=256)*
Control group 
(n=210)*
P value
Sex
Female 140 (54.7) 96 (45.7) 0.06
Male 116 (45.3) 114 (54.3)
Age (years) 73.5 ± 9.5 71.9 ± 11.1 0.31
Current drinker 3 (1.2) 2 (1.0) 0.82
Current smoker 25 (9.8) 19 (9.0) 0.79
Diabetes 76 (29.7) 60 (28.6) 0.83
Atrial fibrillation 2 (0.8) 3 (1.4) 0.5
Systolic BP (mm Hg) 135.3 ± 17.5 135.6 ± 18.4 0.87
Diastolic BP (mm Hg) 70.4 ± 9.7 73.5 ± 9.2 <0.01
HbA1c (%) 7.2 ± 1.0 7.2 ± 1.3 1
LDL (mmol/L) 3.4 ± 0.8 3.0 ± 0.8 <0.01
Antiplatelets 247 (96.5) 194 (92.4) 0.07
Abbreviations: BP = blood pressure; HbA
1c
 = glycated haemoglobin; LDL = low-density 
lipoprotein
* Data are shown as No. (%) or mean ± standard deviation
  #  Choi et al #
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and four restrokes in the control group during the 
intervention period.
Discussion
This study showed that the implementation of a 
secondary stroke prevention programme in GOPCs 
could improve control of cardiovascular risk factors, 
including BP, HbA1c and LDL levels among ischaemic 
stroke patients. We observed an improvement of 
BP control in the intervention group, although 
there was no significant increase in the number of 
antihypertensives used. However, since simvastatin 
was introduced into the GOPC drug formulary in 
2009, the use of statins increased in both the control 
and intervention clinics, although the effect of LDL 
reduction was only observed in the intervention 
group. This result implies that the improvement in 
outcome for this group is due to more than just the 
effects of medications. Lifestyle modifications may 
provide additional benefits.
 Although the BP and HbA1c level in the 
intervention group were comparable with recent 
recommendations (BP <140/90 mm Hg for patients 
without diabetes; BP <130/80 mm Hg and HbA1c 
level of <7% for patients with diabetes), the mean 
LDL levels remained well above the recommended 
target of 1.9 mmol/L. Only about half of the 
patients were taking statins. There is a suggestion 
that doctors may not prescribe or maximise statin 
therapy because treatment may be considered futile, 
especially among older people whose life expectancy 
is limited.15 This trend was observed in both the 
control and intervention sites in this study (Table 
4). The percentage of patients taking statins was 
relatively low in this study as some doctors may have 
TABLE 3.  Changes in clinical parameters and lifestyle modifications before and after the intervention
Abbreviations: BMI = body mass index; BP = blood pressure; HbA
1c
 = glycated haemoglobin; LDL = low-density lipoprotein
* Data are shown as mean ± standard deviation, or No. (%)
† The last values were recorded for patients who had more than one measurement during the intervention phase
‡ Pre-intervention BMI record rate too low for comparison
Intervention group (n=256)* Control group (n=210)*
Pre-intervention Post-intervention P value Pre-intervention Post-intervention P value
Clinical parameter†
Systolic BP (mm Hg) 135.2 ± 17.5 127.7 ± 12.2 <0.01 135.7 ± 18.4 134.5 ± 16.9 0.49
Diastolic BP (mm Hg) 70.4 ± 9.7 68.1 ± 9.3 <0.01 73.5 ± 9.2 72.1 ± 10.6 0.04
HbA1c (%) 7.2 ± 1.0 6.5 ± 0.8 <0.01 7.2 ± 1.3 6.9 ± 0.8 0.13
LDL (mmol/L) 3.4 ± 0.8 2.8 ± 1.3 <0.01 3.0 ± 0.8 3.0 ± 0.7 0.36
BMI‡ (kg/m2) - 24.0 ± 3.6 - 25.5 ± 4.1
Alcohol consumption
Unknown 179 (69.9) 16 (6.3) <0.01 165 (78.6) 160 (76.2) 0.85
Non-drinker 62 (24.2) 225 (87.9) 35 (16.7) 40 (19.0)
Current drinker 3 (1.2) 0 2 (1.0) 1 (0.5)
Ex-drinker 12 (4.7) 15 (5.9) 8 (3.8) 9 (4.3)
Smoking status
Unknown 111 (43.4) 1 (0.4) <0.01 59 (28.1) 19 (9.0) <0.01
Non-smoker 84 (32.8) 187 (73.0) 83 (39.5) 117 (55.7)
Current smoker 25 (9.8) 20 (7.8) 19 (9.0) 17 (8.1)
Ex-smoker 36 (14.1) 48 (18.8) 49 (23.3) 57 (27.1)
Diet
Diet history obtained 52 (20.3) 238 (93.0) <0.01 91 (43.3) 68 (32.4) 0.02
No diet history 204 (79.7) 18 (7.0) 119 (56.7) 142 (67.6)
Exercise
Exercise history obtained 62 (24.2) 237 (92.6) <0.01 54 (25.7) 64 (30.5) 0.62
No exercise history 194 (75.8) 19 (7.4) 156 (74.3) 166 (79.0)
BMI
BMI measured 11 (4.3) 203 (79.3) <0.01 0 40 (19.0) <0.01
No BMI measured 245 (95.7) 53 (20.7) 210 (100) 170 (81.0)
#  Secondary stroke prevention protocol  # 
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TABLE 5.  Statin usage stratified according to age-group
Age-group 
(years)
No. (%) P value
Intervention group (n=256) Control group (n=210)
≤60 13/29 (44.8) 12/37 (32.4) 0.32
61-70 36/70 (51.4) 24/46 (52.2) 1
71-80 42/97 (43.3) 28/81 (34.6) 0.28
≥81 16/60 (26.7) 12/46 (26.1) 1
* Significant difference between pre- and post-intervention data in both groups, P<0.01
TABLE 4.  Comparison of medication use between the intervention and control groups
concerns about the possible side-effects. However, 
no severe adverse effects of statins were noted in 
the intervention group despite the more aggressive 
treatment approach.
 The implementation of secondary stroke 
prevention protocol has raised doctors’ awareness 
of lifestyle modification for patients with ischaemic 
stroke. This was reflected by the significant 
increase in the use of lifestyle modifications in the 
intervention group. We encouraged doctors to 
provide appropriate advice on lifestyle modification 
when lifestyle risk factors were identified during the 
consultation. However, due to heavy patient loads in 
the GOPC, no additional time can be allocated for 
medical consultations. During clinic meetings, our 
staff expressed difficulty in providing quality lifestyle 
education due to limited consultation time. The lack 
of additional resources for lifestyle education was a 
main shortcoming of this programme.
 Certain subgroups of ischaemic stroke patients 
are not well represented by this study, for example, 
those with atrial fibrillation. Atrial fibrillation is 
one of the major risk factors for recurrent stroke.16 
However, as warfarin was not available in the drug 
formulary of the GOPCs during the study period, 
most patients with atrial fibrillation were not 
referred to these clinics. Only a few patients with 
atrial fibrillation were identified in our study and 
all of them had a contra-indication for warfarin. At 
the time of writing, warfarin has become available 
in the GOPCs and several novel anticoagulants have 
been introduced as self-finance items. The use of 
anticoagulants in GOPCs is an important aspect of 
secondary stroke prevention that warrants further 
investigation. 
 Implementation of evidence-based guidelines 
into routine clinical practice is complicated.17,18 
Physicians usually have concerns about the 
applicability of new trial data to individual patients, 
and it takes time for them to change their practice. 
Apart from considering the best available evidence, 
we also need to take into account the practical 
barriers in the clinical practice setting. The heavy 
workload in the clinic, shortage of consultation time, 
and limited scope of the drug formulary may impose 
difficulty in introducing an evidence-based protocol 
to local GOPCs. 
 From the experience of this study, a dedicated 
training session for clinic staff is necessary before 
the implementation of any new protocol. Additional 
review sessions are needed to audit clinicians’ 
compliance with the protocol. Review of the 
GOPC drug formulary, for example, to include 
%
Intervention group (n=256) Control group (n=210)
Pre-intervention Post-intervention Pre-intervention Post-intervention
No. of antihypertensive drugs 
0 15.2 12.9 18.6 14.8
1 44.1 39.5 30.5 33.8
2 30.9 35.9 35.7 32.4
3 9.0 9.8 12.4 14.8
4 0.8 2.0 1.4 3.8
5 0.0 0.0 1.4 0.5
Mean No. of antihypertensive drugs 1.4 1.5 1.5 1.6
Proportion taking statins 17.2 41.8* 21.4 36.2*
Change in statin use
Statin stopped 1.6 4.3
No change 72.3 76.7
Statin initiated 26.2 19.0
Proportion taking antiplatelets 95.3 96.9 91.9 96.2
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greater choices of statins and antiplatelets, may 
be helpful to improve the care of stroke patients. 
Lifestyle modification is an important aspect for 
secondary stroke prevention, but time constraints 
in busy GOPCs are always an issue. A designated 
nurse clinic for patient education and annual risk 
factor monitoring should be introduced. For better 
utilisation of resources, it is beneficial to recruit 
community partners from allied health services to 
provide a structured secondary stroke prevention 
programme for patient empowerment and 
engagement.
 In our study, approximately 5% to 6% of 
patients were lost to other GOPCs and medical 
clinics (Table 1). This may introduce some bias. In 
addition, differences between the two clinics such 
as proportions of health care workers, doctors’ 
qualifications, and differences in the socio-economic 
groups of the patients are possible confounders that 
might introduce bias. The intervention group had a 
higher rate of dropouts due to death and restroke 
although this was not statistically significant. As 
most of these patients had no change in medications 
during the intervention period (Table 1), the higher 
death and restroke rates were unlikely to be related 
to any adverse effects from the implementation 
of the protocol. However, we do not have data on 
the rates of stroke recurrence, adverse events, and 
mortality over a longer period, which are the most 
important outcomes for effective secondary stroke 
prevention. Furthermore, we may need to take into 
account the Hawthorne effect when looking at the 
effectiveness of the protocol implementation, in that 
physicians perform better simply because they are 
aware that they are in a study rather than because of 
the nature of the protocol.19,20 This is an unavoidable 
bias in clinical research. 
Conclusion
This study demonstrates that through 
implementation of a standardised treatment 
protocol, the standard of care of secondary stroke 
prevention for ischaemic stroke patients could 
be improved in local GOPCs. However, due to 
the relatively small sample size in this study, this 
preliminary result should be interpreted with 
caution and further studies involving more primary 
care clinics are required to test its clinical value. 
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